|
ISG15 antiviral mechanism(R)
|
71
|
4
|
0
|
<1.000E-03
|
NUP153,EIF4G2,NUP205,KPNA2
|
|
Viral carcinogenesis(K)
|
206
|
4
|
0.0006
|
1.94E-02
|
KAT2B,RBL2,CCND2,JUN
|
|
HTLV-I infection(K)
|
260
|
4
|
0.0013
|
3.58E-02
|
KAT2B,MAD2L1,CCND2,JUN
|
|
Aurora B signaling(N)
|
40
|
3
|
0.0001
|
7.00E-03
|
BIRC5,NPM1,PSMA3
|
|
Signaling events mediated by HDAC Class I(N)
|
56
|
3
|
0.0002
|
1.17E-02
|
NUP153,KAT2B,YY1
|
|
E2F transcription factor network(N)
|
68
|
3
|
0.0003
|
1.34E-02
|
KAT2B,RBL2,YY1
|
|
Validated targets of C-MYC transcriptional activation(N)
|
72
|
3
|
0.0003
|
1.35E-02
|
BIRC5,CCND2,NPM1
|
|
Mitotic Prophase(R)
|
99
|
3
|
0.0009
|
2.79E-02
|
NUP153,SET,NUP205
|
|
Nonsense-Mediated Decay(R)
|
106
|
3
|
0.0010
|
3.07E-02
|
SMG7,RPL30,RPL7
|
|
Cell cycle(K)
|
124
|
3
|
0.0016
|
3.55E-02
|
RBL2,MAD2L1,CCND2
|
|
Mitotic G1-G1/S phases(R)
|
134
|
3
|
0.0020
|
3.66E-02
|
RBL2,CCND2,PSMA3
|
|
Mitotic Metaphase and Anaphase(R)
|
173
|
3
|
0.0042
|
4.77E-02
|
BIRC5,MAD2L1,PSMA3
|
